Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eisai Ltd ADR (OP: ESALY )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures Product Safety
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
Two Rate Hikes In 2023
This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
Happy Friday
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Exposures US Equities
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Biogen's Alzheimer's Disease Treatment Earns FDA Approval
Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories. 
Via The Motley Fool
Exposures Product Safety
Why Biogen Stock Is On Fire Today
The biotech's controversial Alzheimer's disease drug got a green light from the FDA. 
Via The Motley Fool
Exposures Product Safety
Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib
Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab... 
Via Benzinga
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
Via Benzinga
Exposures Product Safety
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
Wonder Products
Meme is alive and well. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
More Inflationary Pressures
Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%. 
Via Talk Markets
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
Why Biogen's June 7 Aducanumab PDUFA Date Is A High-Risk, High-Reward Catalyst
As the day of reckoning for Biogen Inc.'s (NASDAQ: BIIB) controversial Alzheimer's product candidate aducanumab draws close, an analyst at Oppenheimer looked at the... 
Via Benzinga
A Down Day
The tech wreck continues because inflation will hurt the costly stock sector more than others. 
Via Talk Markets
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
Inflation Shock
Markets are up because jobs data were much better than expected, below 500,000 for the first week since Covid-19 started last week. 
Via Talk Markets
Exposures COVID-19
Tuesday Market Report
Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
Via Talk Markets
Robots
Teva is suffering from fear of the legal risks of its opioid misselling which is overriding good news of its newer drugs. 
Via Talk Markets
Electric Cancer Cure
Most US stocks were down on fear of inflation and financial risks but then rose after lunch. 
Via Talk Markets
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.